Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the
Balanced Expectations Amid Challenges and Opportunities for Johnson & Johnson: Hold Rating Issued
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
Johnson & Johnson's SWOT analysis: oncology portfolio drives growth amid challenges
Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and challenges as it positions itself for long-term growth. Recent financial reports and analyst assessments paint a picture of a company leveraging its strong oncology portfolio and innovative medicine segment to offset headwinds in other areas.
The surprise position Ben Johnson says Bears can 'augment'
Whether Ben Johnson and Ryan Poles think it's a top priority isn't known but the new Bears coach threw out a position they could stand to 'augment.'
Opinion
FOX 323hOpinion
Column: Full of swagger, Ben Johnson is the right choice for the Chicago Bears. He knows it too
Ben Johnson doesn't need clichés to get his point across, nor does he want anything that he didn't earn. He's the right guy for the Chicago Bears. What's better is that he knows it, too.
WTTW4h
Johnson Brushes Off Threat of Arrest for Failing to Help Trump’s Mass Deportation Effort
We are not going to be intimidated by those acts of terror to radically shift our way of living,” Mayor Brandon Johnson said. “That’s what individuals who stoke fear into people want to see happen.”
Ben Johnson Denies Rumored Friction With Lions Coach Dan Campbell
With Ben Johnson off to be the head coach of the Chicago Bears, the Lions will need a new voice to lead the offense. Johnson's move to the division rival has frustrated some fans, and left pundits wondering if there was friction amongst Dan Campbell's coaching staff.
Johnson & Johnson price target lowered to $155 from $170 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.
Jim Cramer Likes Johnson & Johnson (JNJ) and the Kenvue Spin-Off – Here’s Why
We recently published a list of Jim Cramer Discusses TikTok Ban, President Trump & These 6 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses.